Picard Medical Seeks Shareholder Nod for Expanded Equity Plan

Ticker: PMI · Form: DEF 14A · Filed: Sep 29, 2025 · CIK: 2030617

Sentiment: mixed

Topics: Equity Incentive Plan, Stockholder Vote, Executive Compensation, Share Dilution, Corporate Governance, Talent Retention, Warrants

Related Tickers: PMI

TL;DR

**PMI is diluting shareholders to juice executive and employee incentives; vote FOR if you believe in their growth strategy, otherwise, it's a pass.**

AI Summary

Picard Medical, Inc. (PMI) is seeking stockholder approval to amend its 2021 Equity Incentive Plan, increasing the aggregate number of shares available to a total of 18,000,000 shares and including warrants as a new award type. As of September 26, 2025, 73,701,176 shares of common stock were outstanding. The current plan has 719,166 shares available for future awards (0.78% full dilution) and 7,675,194 shares subject to outstanding awards (8.37% full dilution). The proposed amendment would authorize an additional 9,605,640 shares, bringing the total available for future awards to 10,324,806 shares (11.26% full dilution). The Board believes these changes are vital for retaining and incentivizing employees, officers, directors, consultants, and advisors, aligning their interests with long-term stockholder value. The dollar value of equity awards granted as of September 26, 2025, totaled $30,181,362 for executive officers, $6,455,583 for non-executive directors, and $12,788,566 for other employees, based on a closing market price of $8.70.

Why It Matters

This proposal directly impacts Picard Medical's ability to attract and retain top talent in the competitive medical device industry, crucial for innovation and growth. A larger equity pool, totaling 18,000,000 shares, allows PMI to offer more compelling long-term incentives, potentially boosting employee motivation and aligning their financial success with the company's performance. For investors, this could signal management's commitment to growth and employee retention, but also represents potential dilution if not managed effectively. The inclusion of warrants offers additional flexibility in compensation strategies, potentially making PMI more competitive against rivals in securing key personnel.

Risk Assessment

Risk Level: medium — The proposed increase of 9,605,640 new shares for the equity incentive plan, bringing the total to 18,000,000 shares, represents a significant potential dilution of existing shareholder value. While essential for talent retention, this 10.47% increase in full dilution (from 8.37% to 11.26% of outstanding shares) could depress per-share earnings and stock price if not offset by substantial company growth.

Analyst Insight

Investors should vote FOR the proposal if they believe Picard Medical's management team and employees are critical to future growth and that the benefits of enhanced retention outweigh potential dilution. Conversely, investors concerned about dilution without clear performance metrics should consider voting AGAINST.

Financial Highlights

debt To Equity
N/A
revenue
$X
operating Margin
N/A
total Assets
$X
total Debt
$X
net Income
$X
eps
$X
gross Margin
N/A
cash Position
$X
revenue Growth
N/A

Executive Compensation

NameTitleTotal Compensation
Patrick NJ SchnegelsbergExecutive Officer$X
Bernard SkaggsExecutive Officer$X
Matt SchusterExecutive Officer$X

Key Numbers

Key Players & Entities

FAQ

What is Picard Medical, Inc. proposing to change about its 2021 Equity Incentive Plan?

Picard Medical, Inc. is proposing to amend its 2021 Equity Incentive Plan to increase the aggregate number of shares of common stock available to a total of 18,000,000 shares and to include warrants as a new type of award issuable under the plan. This amendment also seeks to ratify the existing 2021 Equity Incentive Plan.

How many shares are currently available under Picard Medical's 2021 Equity Incentive Plan?

As of September 26, 2025, there were 719,166 shares available for future awards under the current 2021 Equity Incentive Plan, representing 0.78% of the full dilution. If the proposal is approved, the total number of shares available for future awards will increase to 10,324,806.

What is the record date for voting at Picard Medical's Special Meeting?

The Board of Directors has fixed the close of business on September 16, 2025, as the record date for determining stockholders entitled to notice of and to vote at the Special Meeting. Only stockholders of record on this date will be eligible to vote.

What is the impact of broker non-votes on Picard Medical's proposal?

The approval of an amendment to the 2021 Equity Incentive Plan is not considered a 'routine' matter under NYSE American LLC rules. Therefore, if you hold shares in 'street name' and do not provide voting instructions, your broker will be unable to vote your shares, resulting in a 'broker non-vote' which will have no effect on the outcome of the vote.

Who are the key executives receiving equity awards at Picard Medical?

The key executives receiving equity awards at Picard Medical include Patrick NJ Schnegelsberg, Chief Executive Officer and Director, with 2,378,124 options; Bernard Skaggs, Chief Financial Officer, with 511,195 options; and Matt Schuster, Chief Operating Officer, with 579,803 options. The total dollar value for all executive officers as a group was $30,181,362 as of September 26, 2025.

What is the purpose of Picard Medical's Amended Incentive Plan?

The purpose of the Amended Incentive Plan is to attract, retain, and motivate individual service providers to Picard Medical and its related companies by offering them the opportunity to acquire an equity interest. It also aims to align their interests and efforts with the long-term interests of the Company’s stockholders, which the Board believes is essential for future success.

What types of awards can be granted under Picard Medical's Amended Incentive Plan?

The Amended Incentive Plan authorizes the grant of Restricted Stock, Restricted Stock Units, Performance Based Awards, Stock Options, Warrants, Stock Appreciation Rights (SARs), and Other Stock or Cash-Based Awards. The inclusion of warrants is a new feature proposed in this amendment.

What is the maximum term for options, warrants, or SARs under the Amended Incentive Plan?

The maximum term for an Option, Warrant, or SAR granted under the Amended Incentive Plan will be 10 years from the grant date. This is subject to earlier termination in accordance with the specific terms of the Amended Incentive Plan and the individual Award Agreement.

How will Picard Medical stockholders attend the Special Meeting?

The Special Meeting will be held entirely online on October 10, 2025, at 8:00 p.m. Eastern Time. Stockholders can attend by visiting the hosting URL: https://www.cstproxy.com/picardmedical/2025 and entering the control number found on their proxy card, voting instruction form, or Notice card.

What are the potential risks of approving the Amended Incentive Plan for Picard Medical stockholders?

The primary risk for stockholders is potential dilution. The proposal to authorize an additional 9,605,640 shares, increasing the total available for future awards to 10,324,806 shares, represents an 11.26% full dilution. This could dilute the ownership percentage of existing stockholders and potentially impact earnings per share if not accompanied by corresponding growth in company value.

Industry Context

Picard Medical, Inc. operates within the medical device industry, a sector characterized by rapid technological advancements, stringent regulatory oversight, and significant competition. Companies in this space focus on innovation to address unmet medical needs and improve patient outcomes. Key trends include the increasing adoption of minimally invasive technologies, the integration of digital health solutions, and a growing demand for personalized medicine.

Regulatory Implications

As a medical device company, Picard Medical, Inc. is subject to extensive regulation by bodies such as the FDA. Compliance with quality standards, manufacturing practices, and post-market surveillance is critical. Changes in healthcare policy or reimbursement rates can also significantly impact the company's financial performance and market access.

What Investors Should Do

  1. Review the proposed amendments to the 2021 Equity Incentive Plan, specifically the increase in authorized shares to 18,000,000 and the addition of warrants, to understand the potential dilution and impact on shareholder value.
  2. Evaluate the company's rationale for increasing equity awards, which is to retain and incentivize key personnel, and assess if the proposed share increase is justified by the company's growth prospects and compensation strategy.
  3. Vote on the proposed amendments at the Special Meeting on October 10, 2025, considering the potential long-term alignment of employee interests with shareholder interests.

Key Dates

Glossary

DEF 14A
A filing with the SEC that provides detailed information about matters to be voted on at a shareholder meeting. (This document contains the proposals and information relevant to the Picard Medical, Inc. special meeting.)
2021 Equity Incentive Plan
A plan established by Picard Medical, Inc. to grant equity-based compensation to employees, officers, directors, consultants, and advisors. (The company is seeking to amend this plan to increase the number of shares available and add warrants.)
Full Dilution
The potential percentage of ownership a shareholder would have if all outstanding options, warrants, and convertible securities were exercised or converted into common stock. (Used to assess the impact of the proposed increase in share reserve on existing shareholders' ownership percentage.)
Warrants
A type of security that gives the holder the right, but not the obligation, to purchase a company's stock at a predetermined price within a specified timeframe. (Warrants are being proposed as a new award type under the amended incentive plan.)
Street Name Holder
A shareholder whose shares are held by a broker, bank, or other nominee rather than being registered directly in their own name. (Affects how these shareholders receive proxy materials and vote their shares.)

Year-Over-Year Comparison

This filing is a proxy statement for a special meeting, focusing on proposed amendments to the equity incentive plan rather than a comprehensive annual review. Therefore, direct year-over-year comparisons of financial metrics like revenue growth or margin changes are not available in this document. The primary focus is on the proposed increase in share authorization from the current plan's availability to 10,324,806 shares, representing an increase in potential dilution.

Filing Stats: 4,701 words · 19 min read · ~16 pages · Grade level 14.1 · Accepted 2025-09-29 17:12:16

Key Financial Figures

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 8 HOUSEHOLDING OF PROXY MATERIALS 9 OTHER MATTERS 10 i PICARD MEDICAL, INC. 1992 E SILVERLAKE, TUCSON AZ, 85713 PROXY STATEMENT FOR SPECIAL Meeting OF STOCKHOLDERS TO BE HELD ON OCTOBER 10, 2025 AT 8:00 p.m., Eastern Time GENERAL INFORMATION As used in this proxy statement, the “Company,” “we,” “us” and “our” refer to Picard Medical, Inc. The term “Special Meeting,” as used in this proxy statement, refers to the Special Meeting of Stockholders and includes any adjournment or postponement of such meeting. When are this proxy statement and the accompanying materials scheduled to be sent to stockholders? This proxy statement and the proxy card will be mailed to you on or about September 29, 2025, shortly after the filing of the definitive proxy statement with the Securities and Exchange Commission (the “SEC”). How do I attend the Special Meeting? The meeting will be held entirely online on October 10, 2025 at 8:00 p.m. Eastern Time at https://www.cstproxy.com/picardmedical/2025. Information on how to vote at the virtual Special Meeting is discussed below. When is the record date for the Special Meeting? The Board of Directors of the Company (the “Board”) has fixed the record date for the Special Meeting as of the close of business on September 16, 2025 (the “Record Date”). Who can vote at the Special Meeting? Only stockholders of record at the close of business on the Record Date will be entitled to vote at the Special Meeting. As of the Record Date, a total of 73,701,176 shares of our common stock were outstanding and entitled to vote. Each share of common stock is entitled to one vote on each matter. What is the difference between a stockholder of record and a “street name” holder? If your shares are registered directly in your name with Continental Stock Transfer

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing